Abivax SA ADR (ABVX)
Abivax Surges on Report Ely Lily is Preparing $17.5 Billion Bid
Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis, met key Phase 3 endpoints, with pivotal maintenance data expected mid-2026. ABVX boasts €589.7 million in cash, supporting operations through Q4 2027, despite high R&D-driven losses and a €15.3 million monthly cash burn.
Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results. Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
French biotech Abivax's shares climb on Eli Lilly bid rumors
French biotech company Abivax's shares jumped by 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly might be interested in bidding for the business.
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster
ABIVAX Société Anonyme [NASDAQ: ABVX] is rated a Strong Buy with a $105 price target, driven by Obefazimod's best-in-class potential for ulcerative colitis (UC). ABVX's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials, targeting a large, fast-growing inflammatory bowel disease market. Upcoming Phase 3 maintenance data in Q2 2026 is a major catalyst, with positive results likely to unlock significant upside for ABVX shares.
Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst
Abivax shares surged 500% after positive phase 3 results for obefazimod in moderate-to-severe ulcerative colitis, achieving significant clinical remission at 8 weeks induction period. Both ABTECT-1 and ABTECT-2 studies showed statistically significant results, supporting obefazimod's differentiated safety and efficacy profile as a first-in-class oral miR-124 enhancer. The next major catalyst is the 44-week maintenance trial data, expected in Q2 2026, which could enable a New Drug Application filing of obefazimod in H2 2026.
Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity
Obefazimod's strong Phase 3 induction data positions Abivax as a leading UC contender, with a novel mechanism and favorable safety profile. The ABTECT program's robust design and inclusion of hard-to-treat patients de-risk obefazimod's path to approval, though maintenance data in 2026 remains pivotal. Obefazimod's differentiation lies in efficacy without serious safety risks, targeting a multi-billion dollar market despite intense competition from established and emerging drugs.
Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout
Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism modulates inflammation without broad immune suppression, potentially reducing infection risks, unlike traditional immunosuppressants. Upcoming phase 3 trial data in Q3 2025 is a key catalyst, with a high probability of success based on strong phase 2 results.
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?
The consensus price target hints at a 360.5% upside potential for Abivax SA Sponsored ADR (ABVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
